The FLRT3-UNC5B Pathway is a Novel Regulator of T Immunosurveillance
Flies D, Yan C, Yang Q, Arbitman S, Fitzgerald D, Sharee S, Shaik J, Bosiacki J, Myers K, Paucarmayta A, Johnson D, O'Neill T, Cusumano Z, Langermann S, Langenau D, Patel S. The FLRT3-UNC5B Pathway is a Novel Regulator of T Immunosurveillance. The Journal Of Immunology 2024, 212: 0298_5492-0298_5492. DOI: 10.4049/jimmunol.212.supp.0298.5492.Peer-Reviewed Original ResearchT cell activationT cellsCell-derived xenograftsTumor growthT cell anti-tumor immunityInhibitor of T cell activationCell-derived xenograft modelControl T cell responsesHuman T cell functionT cell checkpointsAnti-tumor immunityT cell responsesT cell functionActivated T cellsTumor-immune interactionsPromote tumor growthHuman T cellsCAR-TUNC-5 netrin receptor BZebrafish tumor modelTumor cellsTumor modelReceptor BGain-of-function screenMonoclonal antibodiesThe FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies
Prajapati K, Yan C, Yang Q, Arbitman S, Fitzgerald D, Sharee S, Shaik J, Bosiacki J, Myers K, Paucarmayta A, Johnson D, O’Neill T, Kundu S, Cusumano Z, Langermann S, Langenau D, Patel S, Flies D. The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies. Science Advances 2024, 10: eadj4698. PMID: 38427724, PMCID: PMC10906930, DOI: 10.1126/sciadv.adj4698.Peer-Reviewed Original ResearchConceptsFibronectin leucine-rich transmembrane protein 3T cellsHuman T cellsCancer immunotherapyT cell-based cancer immunotherapyInhibit T cell activationT cell checkpointsActivated human T cellsT cell immunityT cell killingT cell activationHuman cancer modelsImmune-dependent mannerAxon guidance proteinsTarget such mechanismsCAR-TCoinhibitory receptorsGuidance proteinsTumor immunityClinical benefitCancer modelsTumor growthCancer cellsHuman cancersMonoclonal antibodies